Insmed execs sold millions in company stock, but analysts maintain a "Moderate Buy" rating.

Insmed Incorporated's executives, including CFO Sara Bonstein, COO Roger Adsett, and CEO William Lewis, have recently sold significant amounts of company stock, totaling millions of dollars. Despite these sales, large investors have increased their stakes, and analysts have maintained a "Moderate Buy" consensus with a target price of $85. Insmed, a biopharmaceutical company, develops treatments for rare diseases, with its first product, ARIKAYCE®, approved for treating lung disease.

5 weeks ago
6 Articles

Further Reading